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Background and aims: OATP1B3 is an organic anion transporting polypeptide (OATP) that 
functions as a multispeciﬁ  c transporter in the normal liver. We examined the expression and 
clinical signiﬁ  cance of OATP1B3 in colon cancers in tissue microarrays.
Methods: Immunohistochemistry was used to assess OATP1B3 protein expression in paraf-
ﬁ  nized colon tumor tissue microarrays. OATP1B3 immunostaining was evaluated by location 
and intensity. Relationships between OATP1B3 expression, known prognostic variables and 
clinical outcomes were examined.
Results: 278 colon tumor samples of all stages were evaluated for OATP1B3 expression. 
OATP1B3 immunostaining was detectable in the majority (56%) of the tumor samples. Higher 
OATP1B3 expression was seen in lower stage tumors (p = 0.003) and lower grade (p = 0.004) 
tumors, but was not predictive of 5-year survival or tumor recurrence as an independent variable. 
Within individual tumor grades, OATP1B3 expression was associated with improved 5-year 
survival, but not recurrence in patients with poorly differentiated tumors.
Conclusion: OATP1B3 expression was seen in the majority of colon tumors and may be 
a marker of lower grade and lower stage tumors and may predict for improved outcome in 
certain tumors.
Keywords: tissue array analysis, colon neoplasms, organic anion transporters, tumor markers, 
immunohistochemistry
Introduction
Colorectal cancer is a global public health problem, annually accounting for over 
1 million new cases of cancer and about half a million deaths.1,2 Surgical resection is 
the only curative therapy for colon cancer, but more than two-thirds of the patients 
who undergo resection will have a signiﬁ  cantly high risk of tumor recurrence. Several 
studies have now demonstrated that disease recurrence can be reduced by adminis-
tering adjuvant chemotherapy (using 5-FU with or without oxaliplatin).3 The role of 
adjuvant treatment is well established in stage III cancer, but remains controversial in 
patients with stage II disease. Patient care could be substantially improved by identi-
fying patients within a staging group that are at high versus low risk for recurrence. 
To this end, tumor speciﬁ  c changes have been evaluated for their possible prognostic 
signiﬁ  cance; to date however the data are insufﬁ  cient to support use of these markers 
to predict outcomes and clinicians still depend largely on the commonly used measures 
of tumor stage and histological grade to make therapeutic decisions.
In an attempt to discover novel factors affecting tumor cell survival, our investiga-
tion revealed that OATP1B3 (SLCO1B3, GeneID: 10599), a member of the organic 
anion transporting polypeptide (OATP/SLCO) superfamily is markedly overex-
pressed in a majority of colon tumors in comparison to normal colon tissues and may Clinical and Experimental Gastroenterology 2008:1 2
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be associated with differing sensitivity to chemotherapy.4 
OATP1B3 expression has been previously demonstrated 
in tumor cell lines from a variety of gastrointestinal malig-
nancies.5 OATP1B3 has been considered a “liver-speciﬁ  c” 
transporter that when expressed in the normal liver acts as an 
uptake transporter for a variety of endogenous compounds 
(eg, bile acids, cholecystokinin, conjugated steroids, thyroid 
hormones) as well as xenobiotic compounds (eg, pravastatin, 
paclitaxel).5–7 It is not known whether the ectopic expression 
of OATP1B3 in the cytoplasm of colon tumors represents a 
potential mechanism for altered cellular behavior, but data 
from other investigations indicate a possible link between the 
expression of OATP1B3 and clinical outcomes in patients 
with breast cancer.8
In this study, we aimed to determine whether OATP1B3 
expression conferred any prognostic signiﬁ  cance by ret-
rospectively examining the expression of OATP1B3 in 
a large collection of colon tumor samples where clinical 
follow-up information was available. We now demonstrate 
that OATP1B3 is expressed in the majority of primary colon 
tumors and that the expression of this transporter may have 
clinical or pathological value.
Materials and methods
Tissue samples
De-identiﬁ  ed, archival cases of colorectal cancer from three 
tissue microarrays (TMAs) were analyzed for their expression 
of OATP1B3. The TMA available through the Vanderbilt 
GI SPORE and compiled by Dr Washington contained 
93 evaluable colorectal tumor samples of all American 
Joint Committee on Cancer criteria (AJCC) stages as well 
as associated clinical information. A TMA provided by 
Dr Resnick contained 101 evaluable colon cancer samples 
retrieved nonselectively from the archives of the Department 
of Pathology at the Rhode Island Hospital between the years 
of 1983 and 1994. All tumors from this TMA were AJCC 
stage II and the patients did not receive treatment in the adju-
vant setting. Recurrence and survival data were ascertained 
through the Rhode Island Tumor Registry. A TMA provided 
by Dr Yeatman contained 67 evaluable samples from patients 
with colorectal cancer at all stages as well as associated clini-
cal information. The acquisition of all the human tissues was 
in accordance with and approved by the ethics committees 
at the respective institutions. Tissue samples were formalin-
ﬁ  xed and parafﬁ  n embedded. All cases had been previously 
reviewed after hematoxylin and eosin staining to conﬁ  rm the 
diagnoses and the adequacy of material. Clinical data com-
mon to all three TMAs (patient demographics, tumor stage, 
tumor grade, tumor recurrence and survival) was combined 
for the purposes of statistical analysis.
Clinicopathological features
Combining the three TMAs there were 278 evaluable tissue 
samples for OATP1B3 expression. In addition to OATP1B3 
expression, the following variables were available on all the 
samples: patient age, gender, race, tumor stage, lymph node 
status, metastases, tumor grade and overall survival. The 
frequency and distribution of these factors is presented in 
Table 1. The mean age of the patients at the time of speci-
men procurement was 70 years (range, 10–96 years). There 
were tumors from 143 men and 135 women with a median 
duration of follow-up of 48 months (range, 0–204 months). 
Table 1 Clinicopathologic characteristics of 278 colon cancer 
patients
Variable n (total = 278)
Age at surgery (y)
 Median 70
 Range 10–96
Sex
 Male 143
 Female 135
Differentiation
 High-grade 105
 Low-grade 169
 Unknown 4
Tumor stage
 11 7
 2 163
 36 6
 43 2
Lymphovascular invasion
 Absent 223
 Present 50
 Unknown 5
Recurrence
 No 173
 Yes 72
  Not applicable or unknown 33
Survival
 Dead 95
 Alive 183
OATP1B3 expression
  Negative/Low staining (intensity = 0 or 1) 123
  Medium level staining (intensity = 2) 90
  High level staining (intensity = 3) 65Clinical and Experimental Gastroenterology 2008:1 3
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Tumor grade as deﬁ  ned by the AJCC were distributed as 
follows: 168 high-grade and 96 low-grade.9 Tumor stages 
were distributed as follows: stage I (n = 17), stage II 
(n = 163), stage III (n = 66), and stage IV (n = 32). Ninety-
ﬁ  ve patients died during the follow-up period.
Immunohistochemistry
OATP1B3 expression was determined by immunohisto-
chemical (IHC) staining using a polyclonal OATP1B3 
antiserum (raised against the C-terminal peptide sequence 
of OATP1B3 and previously verified for specificity).10 
Because of the known expression of OATP1B3 in normal 
human hepatocytes,6 liver sections served as positive con-
trols and were used to conﬁ  rm the speciﬁ  city of OATP1B3 
antiserum by antigenic peptide blocking (Figure 1A). Tissue 
specimens were deparafﬁ  nized using EZ-Dewax (BioGenex, 
San Ramon, CA, USA), followed by antigen retrieval using 
citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6). 
Sections were incubated with a peroxidase blocking reagent 
to quench endogenous peroxidase activity. After incubation 
with blocking buffer for 1 hr, the slides were incubated 
with the rabbit polyclonal OATP1B3 antiserum (1:200) for 
2 hours at room temperature. To avoid nonspeciﬁ  c avidin-
biotin interactions, a commercially available blocking kit was 
used (Avidin Biotin Blocking kit, BioGenex). After wash-
ing, sections were incubated with biotinylated anti-rabbit 
IgG (BioGenex) for 20 min and then with streptavidin-HRP 
conjugate (BioGenex) for 20 min. After washes, the immune 
reaction was visualized using 3,3’-diaminobenzidine (DAB, 
BioGenex) and nuclei were counter-stained with hematoxy-
lin. The speciﬁ  city of immunoreactive signals was veriﬁ  ed 
by omitting either primary or secondary antibody as well as 
Figure 1 Immunohistochemical staining and immunoblotting for OATP1B3. A) Human liver section shows intense membraneous expression of OATP1B3. The speciﬁ  city of 
OATP1B3 immunostaining was conﬁ  rmed by negative staining with OATP1B3 antibody pre-incubated with the antigenic peptide. B) Normal colon tissue showing no detectable 
immunostaining, except in stromal inﬂ  ammatory cells. C, D, and E) Colon tumor tissues showing negative C) and positive (moderate D) or high E)) OATP1B3 immunostaining. 
F) Immunoblotting for OATP1B3 showing OATP1B3 expression in three out of four paired colon tumor tissues, but not in normal tissues from the same donors.Clinical and Experimental Gastroenterology 2008:1 4
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by incubating with polyclonal OATP1B3 antiserum that has 
been neutralized by pre-incubation with the antigenic peptide 
at 37 °C for 2 hours.
Immunoblotting
To further conﬁ  rm the overexpression of OATP1B3 in colon 
tumors and to examine the possibility of OATP1B3 expres-
sion in normal colonic tissues from patients with cancer, 
immunoblotting was performed on a limited number of pro-
tein lysates prepared from normal and cancerous colonic tis-
sues from the same donors (n = 4 pairs). Tissue homogenates 
were prepared in RIPA buffer [50 mM Tris, pH 7.6/150 mM 
NaCl/1 mM EDTA/1% Nonidet P −40/2.5 mg/ml NaDOC 
containing protease inhibitors (Complete, Roche, Pleasanton, 
CA, USA)] and centrifuged at 13,000 rpm for 10 minutes 
to collect the supernatant. Tissue homogenate containing 
25 μg of total protein was prepared in SDS/PAGE sample 
buffer and boiled at 95 °C for 10 minutes and subjected to 
protein electrophoresis and eletrotransfer. The blots were 
probed with a polyclonal OATP1B3 antiserum and β-actin 
(cell signaling). Bound antibody was detected on ﬁ  lm by 
using appropriate secondary antibody/HRP conjugates and 
an enhanced chemiluminescence kit (Amersham Pharmacia, 
Piscataway, NJ, USA).
Pathologic evaluation
OATP1B3 expression was evaluated in all tissue sections 
within 14 days of IHC staining and scored independently by 
an experienced pathologist (E.H.) who had no knowledge of 
the clinicopathologic features or clinical outcome. For each 
tumor section, OATP1B3 expression was assessed according 
to the percentage of tumor cells that demonstrated staining, 
cellular location and intensity of staining (graded as negative/
low [grade 0 or 1], moderate [grade 2], or high [grade 3]). The 
location of immunostaining was designated as cytoplasmic, 
nuclear or membranous. OATP1B3 expression was assigned 
as “negative” if the staining intensity was grade 1 or less or in 
less than 5% of the tumor cells. Expression was designated as 
“positive” if the staining was grade 2 or greater in at least 5% 
of the tumor cells. Positive expression was subcategorized 
into moderately (grade 2) or strongly positive (grade 3).
Statistical analysis
Contingency tables and Fisher’s exact test11 were used to 
determine the univariate relationship between OATP1B3 
expression and each categorical clinical variable including 
patient demographics and known prognostic factors such as 
tumor stages and tumor grade. Multiple logistic models were 
used to examine categorical outcomes (eg, recurrence, 5-year 
survival) with OATP1B3 expression as a potential predictor 
and as well as other prognostic variables (eg, stage, tumor 
grade) as covariates when necessary.
Results
OATP1B3 expression in colorectal 
tumor samples
Positive expression (grade 2 or higher) for OATP1B3 protein 
was detected in the majority (55.8%) of the tumor samples 
assessed. Of the tumors with positive expression, 90 (32.4%) 
tumor samples had a moderate level of OATP1B3 staining 
and 65 (23.4%) tumor samples had a high level of OATP1B3 
staining (Figure 1). Colon tumor sections showed positive 
OATP1B3 expression localized to the cytoplasm which 
was clearly different from the exclusive membrane expres-
sion seen in the liver (Figure 1A). Table 2 summarizes the 
distribution of OATP1B3 expression at various tumor stages 
and there was a statistically signiﬁ  cant association between 
OATP1B3 expression and tumor stage with a tendency 
towards higher OATP1B3 expression in lower stage tumors 
(p = 0.003, Fisher’s exact test). There was also a statisti-
cally signiﬁ  cant association between OATP1B3 expression 
and tumor grade with a tendency towards higher OATP1B3 
expression (high level staining) in lower grade or more highly 
differentiated tumors (p = 0.004, Fisher’s exact test).
Correlation of OATP1B3 expression 
and tumor stage or grade with 5-year 
survival and tumor recurrence
As a single variable, OATP1B3 expression was assessed 
for its contribution to patient survival and tumor recurrence 
using Fisher’s exact test. There was a statistically signiﬁ  -
cant relationship between OATP1B3 expression and 5-year 
survival (p = 0.001) where a higher proportion of patients 
died prior to the 5-year milestone if they demonstrated nega-
tive expression versus positive (moderate or high staining) 
expression. Similarly, there was a statistically signiﬁ  cant 
relationship between OATP1B3 expression and the incidence 
of tumor recurrence in patients with cancers of stages I, II, 
and III (p = 0.037). The rate of tumor recurrence was higher 
in patients if they demonstrated negative expression versus 
positive expression.
However, given the association between OATP1B3 
expression and tumor stage, we further tested whether 
the association between OATP1B3 expression and 5-year 
survival or tumor recurrence was related to OATP1B3 Clinical and Experimental Gastroenterology 2008:1 5
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expression being an identiﬁ  er of earlier stage tumors. Logistic 
regression analysis indicated that there was no statistically 
signiﬁ  cant difference in 5-year survival or tumor recurrence 
when OATP1B3 expression was examined within individual 
stages (p   0.05). These results suggest that OATP1B3 
expression may be an indicator of earlier stage tumors rather 
than being an independent predictor of patient survival or 
tumor recurrence.
Given the association between OATP1B3 expression 
and tumor grade, we also examined the possibility that 
OATP1B3 expression may be an indicator of lower tumor 
grade or highly differentiated tumor status. Logistic regres-
sion analysis indicated that there was a statistically signiﬁ  cant 
difference in 5-year survival when OATP1B3 expression 
was examined within the same tumor grade groups. In the 
poorly differentiated tumor group, a higher proportion of 
patients were alive 5 years or longer if they demonstrated 
positive expression versus negative expression (p = 0.021). 
However, this relationship was not found in patients with 
well differentiated tumors. A similar analysis was performed 
for tumor recurrence, but no relationship was found to be 
statistically signiﬁ  cant. These results suggest that OATP1B3 
expression may have prognostic value for patient survival 
within a particular tumor grade group.
OATP1B3 expression in normal 
and cancerous colonic tissues 
from the same donors
The results from OATP1B3 immunoblotting confirm 
that OATP1B3 protein is expressed in colon tumors, but 
not in the adjacent normal colonic tissues from the same 
donor (Figure 1E). The majority of tumors (n = 3 out of 4) 
showed expression of OATP1B3, consistent with the 
Table 2 Association between OATP1B3 expression/immunostaining and clinicopathological parameters in 278 colon cancers
OATP1B3 expression (Total n = 278)
Variable
subgroup Negative Positive p-value
n (n = 123) Moderate (n = 90) High (n = 50)
Age at surgery (y) 66.1 ± 15.8 68.7 ± 13.1 70.0 ± 12.4 0.146
Sex 0.312
 Male  (n  = 135) 135 54 40.0% 49 36.3% 32 23.7%
 Female  (n  = 143) 143 69 48.3% 41 28.7% 33 23.1%
Differentiation 0.004
 High-grade  (n  = 168) 168 80 47.6% 60 35.7% 28 16.7%
 Low-grade  (n  = 96) 96 42 43.8% 28 29.2% 36 37.5%
 unknown  (n  = 4) 41 2 1
Tumor stage 0.003
 1  (n  = 17) 17 6 35.3% 7 41.2% 4 23.5%
 2  (n  = 163) 163 67 41.1% 45 27.6% 51 31.3%
 3  (n  = 66) 66 38 57.6% 24 36.4% 4 6.1%
 4  (n  = 32) 32 12 37.5% 14 43.8% 6 18.8%
Lymphovascular invasion 0.727
 No 222 99 44.6% 69 31.1% 54 24.3%
 Yes 52 21 40.4% 20 38.5% 11 21.2%
 unknown 4 3 1 0
Recurrence (Stages I, II, and III only)* 0.037
 No 173 70 40.5% 55 31.8% 48 27.7%
 Yes 72 41 56.9% 20 27.8% 11 15.3%
  unknown or stage IV 33 12 15 6
Overall survival (All stages, n = 278) 0.001
   5 years 112 44 39.3% 29 25.9% 39 34.8%
   5 years 166 79 47.6% 61 36.7% 26 15.7%
Note: *Stage IV patients were not included in the tumor recurrence analysis.Clinical and Experimental Gastroenterology 2008:1 6
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immunohistochemistry results using the TMAs. OATP1B3 
expression in colon tissue appears to be tumor-speciﬁ  c and 
not intrinsic to individual patients.
Discussion
In our current study, we demonstrate that OATP1B3 is 
expressed in a majority of colorectal tumors across all tumor 
stages. The staining pattern of OATP1B3 was mainly cyto-
plasmic, clearly different from the membraneous expression 
pattern in liver. We assessed the expression of this protein 
and its prognostic significance in a cohort of archived 
tumor samples of various AJCC stages. In this retrospective 
analysis, positive OATP1B3 expression was associated with 
earlier stage tumors and lower grade tumors and therefore 
expectedly associated with improved clinical outcomes. 
When individual tumor stages were considered, OATP1B3 
expression was not associated with differing clinical out-
comes. However, within individual tumor grades, OATP1B3 
expression was associated with improved 5-year survival in 
patients with poorly differentiated tumors. The results indi-
cate that OATP1B3 expression may have prognostic value 
for patient survival within a particular tumor grade group. 
These ﬁ  ndings are consistent with recent reports indicating 
an association between high OATP1B3 expression levels 
and highly differentiated breast cancers.8
In this study we were aiming to assess whether OATP1B3 
expression had prognostic signiﬁ  cance within a particular 
tumor stage and in particular whether OATP1B3 expres-
sion affected tumor recurrence or survival. To optimally 
assess the recurrence question retrospectively using a tissue 
array, we enriched our tumor population using an array from 
Dr Resnick containing only Stage II tumors. Our goal being 
to possibly identify tumor characteristics that could differ-
entiate between patients within a staging group that are at 
high versus low risk for recurrence, such that chemotherapy 
can be administered to patients at high risk to reduce their 
incidence of tumor relapse or avoided in patients who are at 
low risk and unlikely to receive beneﬁ  t from treatment. In our 
study, OATP1B3 expression was not associated with differ-
ing outcomes within a particular stage, but may be helpful in 
distinguishing between poorly differentiated tumors. Future 
studies involving larger numbers of samples will be helpful 
to conﬁ  rm and further clarify this relationship.
Members of the organic anion transporting polypeptide 
(OATP/SLCO) family represent multispeciﬁ  c transporters 
that mediate the transport of many endogenous (bile acids, 
cholecystokinin, conjugated steroids, thyroid hormones) 
and xenobiotic substrates (including commonly used 
chemotherapeutic agents such as irinotecan, methotrexate 
and paclitaxel).5,12–16 Our study is the ﬁ  rst to demonstrate 
that OATP1B3 is commonly expressed in colorectal cancer 
with a cytoplasmic expression pattern. The functional sig-
niﬁ  cance of the ectopic expression of this protein in colon 
cancer remains to be clariﬁ  ed. Considering the substrates of 
OATP1B3 (bile acids and other hormonal substrates), the 
expression of this protein may have a functional impact on 
colorectal tumorigenesis and tumor cell behavior.
Future studies may be indicated to examine the associa-
tion between OATP1B3 expression and clinical outcomes 
in various tumors including colorectal cancers. Studies to 
evaluate the functional signiﬁ  cance, timing and regulation 
of OATP1B3 overexpression are ongoing.
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